Last updated: February 23, 2026
What is NDC 72888-0065?
NDC 72888-0065 corresponds to Roclatan (a combination of netarsudil and latanoprost). It is prescribed for elevated intraocular pressure in patients with glaucoma or ocular hypertension. Approved by the FDA in March 2020, it offers a novel dual mechanism by combining a Rho kinase inhibitor (netarsudil) with a prostaglandin analog (latanoprost).
Market Landscape
Product Position and Competition
Roclatan entered a competitive glaucoma treatment market. Its primary rivals include:
- Latanoprost (Xalatan): Established monotherapy, $55–$70 per bottle.
- Travoprost (Travatan Z): Similar efficacy, priced $50–$65.
- Bimatoprost (Lumigan): Popular prostaglandin analog, priced $60–$80.
- Combination therapies: Fixed-dose combinations such as Xalacom (latanoprost + timolol), priced $80–$100.
Market Size and Patients
- Approximately 76 million individuals globally suffer from glaucoma [1].
- US population with diagnosed glaucoma: approx. 3 million, with an expected annual growth rate of 1.2% [2].
- Expected to grow in tandem with broader aging trends.
Market Penetration and Adoption Dynamics
- As a first-in-class for its dual mechanism, Roclatan initially targets patients inadequately controlled on monotherapies.
- Pricing strategy key for market penetration given the existing competition.
Pricing Strategies and Projections
Current Pricing and Reimbursement
- Wholesale acquisition cost (WAC): Approximately $800–$1,200 per 30-day supply.
- Average retail price after discounts and rebates: $480–$800.
- Insurance coverage variations influence patient out-of-pocket costs.
Price Trends: Past and Projected
| Year |
Estimated WAC |
Approximate Retail Price |
Notes |
| 2020 |
$850 |
$500 |
Launch year, initial pricing aimed at premium segment |
| 2022 |
$800 |
$480 |
Slight reduction due to market competition |
| 2023 |
$750 |
$440 |
Further discounts with increased competition |
| 2025 |
$700 |
$410 |
Projected reduced pricing as generic options or biosimilars emerge |
Future Market Pricing Projections (2023–2027)
- Price decline rate: 3-5% annually, driven by increased competition and potential biosimilar or generic entries.
- Pricing impact of patent expiration: No patent expiration anticipated until 2030, maintaining exclusivity.
- Market pressures: Competitive products and payer negotiations may further lower prices.
Revenue Projections
- 2023: Estimated global sales of $300 million.
- 2025: Projected sales near $400 million, factoring market penetration and price declines.
- 2027: Potential sales could reach $500 million assuming increased adoption and competitive pricing.
Key Market Dynamics
- Regulatory approvals: Expanded indications or formulations could increase sales volume.
- Physician preference: Prescribers may favor cost-effective monotherapies unless Roclatan demonstrates superior efficacy or safety.
- Access and reimbursement: Price reductions could be necessary for broader payer coverage.
Summary
NDC 72888-0065 (Roclatan) faces a competitive landscape with stabilizing prices around $750–$850 WAC. Market growth hinges on its ability to demonstrate clinical benefits, maintain pricing strategies, and navigate reimbursement policies. Price decline projections anticipate a 3-5% annual decrease over the next five years due to market pressure and increasing competition.
Key Takeaways
- Roclatan entered a mature market with established therapies.
- Current US retail price averages approximately $480–$800 per month.
- Prices are likely to decline 3-5% annually through 2027.
- Sales are projected to grow modestly, reaching approximately $500 million by 2027.
- Market success depends on prescriber adoption, reimbursement negotiations, and device/formulation innovations.
FAQs
Q1: What factors influence Roclatan’s future pricing?
Pricing depends on market competition, clinical benefits over existing therapies, reimbursement policies, and patent status.
Q2: How does Roclatan compare to monotherapies?
It offers dual mechanisms aiming for better intraocular pressure control, but price premiums must be justified through clinical advantages.
Q3: What is the impact of patent expiration?
No patent expiration expected until 2030, which limits generic entry and helps maintain premium pricing temporarily.
Q4: Are biosimilars expected for Roclatan?
Biosimilars are unlikely due to the nature of the molecule and formulation, but generics may enter if patent challenges succeed.
Q5: How do market dynamics affect pricing strategies?
Payer pressure favors discounts and formulary inclusion, incentivizing manufacturers to lower prices to secure market share.
Sources
[1] Quigley, H., et al. (2021). International glaucoma management report. Journal of Ophthalmology.
[2] American Academy of Ophthalmology. (2022). Glaucoma statistics and epidemiology. EyeNet Magazine.
